Novo Nordisk Cash Flow from Operating Activities 2010-2024 | NVO

Novo Nordisk annual/quarterly cash flow from operating activities history and growth rate from 2010 to 2024. Cash flow from operating activities can be defined as a company's cash flows from operations.
  • Novo Nordisk cash flow from operating activities for the quarter ending March 31, 2024 was $2.084B, a 51.49% decline year-over-year.
  • Novo Nordisk cash flow from operating activities for the twelve months ending March 31, 2024 was $40.935B, a 28.01% increase year-over-year.
  • Novo Nordisk annual cash flow from operating activities for 2023 was $15.813B, a 41.57% increase from 2022.
  • Novo Nordisk annual cash flow from operating activities for 2022 was $11.17B, a 27.65% increase from 2021.
  • Novo Nordisk annual cash flow from operating activities for 2021 was $8.751B, a 9.95% increase from 2020.
Novo Nordisk Annual Cash Flow Ops
(Millions of US $)
2023 $15,813
2022 $11,170
2021 $8,751
2020 $7,959
2019 $7,013
2018 $6,822
2017 $6,253
2016 $7,179
2015 $5,697
2014 $5,651
2013 $4,620
2012 $3,839
2011 $3,995
2010 $3,509
2009 $2,880
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $598.098B $33.708B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $834.732B 120.64
Johnson & Johnson (JNJ) United States $366.658B 14.54
Merck (MRK) United States $315.030B 57.32
AbbVie (ABBV) United States $305.760B 15.80
AstraZeneca (AZN) United Kingdom $245.469B 21.34
Novartis AG (NVS) Switzerland $220.139B 15.30
Pfizer (PFE) United States $167.164B 20.77
Sanofi (SNY) $127.725B 12.04
Innoviva (INVA) United States $1.113B 7.82